Insights from 2024 EHA Annual Meeting

 

Videos
04:03

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma

FEATURING Wojciech Jurczak
  • July 1, 2024
05:27

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Updated Trends in Real-World Outpatient Administration of CAR-T in R/R NHL

FEATURING Radhika Bansal
  • June 30, 2024
06:39

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Axicabtagene Ciloleucel in R/R Primary Mediastinal B-Cell Lymphoma

FEATURING Jean Galtier
  • 10 views
  • June 30, 2024
12:32

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sequential Administration of Bispecific Antibodies and Anti-BCMA CAR-T in R/R MM

FEATURING David Fandrei
  • 1 view
  • June 30, 2024
06:51

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL With TP53 Mutations

FEATURING Wojciech Jurczak
  • 1 view
  • June 30, 2024
10:03

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax for Treatment-Naïve CLL/SLL With Del(17p) and/or TP53

FEATURING Paolo Ghia
  • 3 views
  • June 28, 2024
12:04

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: The Impact of TP53 Mutation Burden on Risk & Treatment Decision in Newly Diagnosed CLL

FEATURING Maher Salamoon
  • 7 views
  • June 28, 2024
06:54

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory WM/LPL

FEATURING Mazyar Shadman
  • 12 views
  • June 28, 2024
05:41

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL

FEATURING Catherine Coombs
  • 4 views
  • June 28, 2024
06:30

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ AML Patients Receiving Chemo + Quizartinib vs. Placebo

FEATURING Esther Oliva
  • 2 views
  • June 28, 2024
11:23

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML

FEATURING Jorge Cortés
  • June 28, 2024
14:39

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: REVIVE Study - Updated Long-Term Results of Hepcidin Mimetic Rusfertide in PV

FEATURING Kristen Pettit
  • June 28, 2024
04:33

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Daratumumab for iTTP

FEATURING Júlia Weisinger
  • 19 views
  • June 28, 2024
36:10

Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

FEATURING Samer Al Hadidi
  • 57 views
  • June 27, 2024
09:52

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors

FEATURING Joshua Zeidner
  • 17 views
  • June 26, 2024
11:40

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML

FEATURING Wei-Ying Jen
  • 23 views
  • June 26, 2024
10:27

Insights from 2024 EHA Annual Meeting

Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL

FEATURING Jose-Maria Ribera
  • 47 views
  • June 24, 2024
19:14

2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA

FEATURING Kerry Rogers, Jennifer Woyach
  • 177 views
  • June 21, 2024
07:38

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - Analyzing Therapy Lines and BTKi Response

FEATURING Manali Kamdar
  • 25 views
  • June 20, 2024
12:24

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM

FEATURING Pieter Sonneveld
  • 7 views
  • June 20, 2024
12:00

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in AML Pts With Myelodysplasia-Related Changes

FEATURING Maria Teresa Voso
  • 33 views
  • June 20, 2024